Alkermes' Board of Directors joins original founders, current leadership and outside experts; together they maintain the corporate trajectory.
- Richard F. Pops, Chairman
- Michael A. Wall, Chairman Emeritus
- Floyd E. Bloom
- Robert A. Breyer
- David A. Broecker
- Gerri Henwood
- Paul J. Mitchell
- Alexander Rich
- Mark Skaletsky
Richard F. Pops
Chairman
Mr. Pops became Chairman of Alkermes in April 2007. From 1991-2007, he served as Chief Executive Officer of Alkermes. Under his leadership, Alkermes grew from a privately held company with 25 employees to a publicly traded pharmaceutical company with more than 800 employees in multiple locations in the United States. Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; CombinatoRx, Inc.; Acceleron Pharma, Inc.; Sirtris Pharmaceuticals, Inc.; the Biotechnology Industry Organization (BIO); the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Harvard Medical School Board of Fellows.
Michael A. Wall
Chairman Emeritus
Mr. Wall is a founder of Alkermes and was Chairman of the Board of Alkermes from 1987-2007. He is currently Chairman Emeritus of Alkermes. From April 1992 until June 1993, he was a director and Chairman of the Executive Committee of Centocor, Inc. From November 1987 to June 1993, he was Chairman Emeritus of Centocor.
Floyd E. Bloom
Dr. Bloom is a founder of Alkermes and has been a director of Alkermes since 1987. Dr. Bloom has been active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health and The Salk Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and is currently Professor Emeritus. Dr. Bloom served as Editor-in-Chief of Science from 1995 to May 2000. He holds an A.B. (Phi Beta Kappa) from Southern Methodist University and an M.D. (Alpha Omega Alpha) from Washington University School of Medicine in St. Louis. He is a member of the National Academy of Science, the Institute of Medicine, the Royal Swedish Academy of Science, the President's Council on Bioethics, Veteran's Administration - Gulf War Veteran Illness and the Washington University Board of Trustees. Dr. Bloom also serves on the Board of Directors of Elan Pharmaceuticals and the Scientific Advisory Boards of MiddleBrook Pharmaceuticals, and RxGen.
Robert A. Breyer
Mr. Breyer has been a director of Alkermes since July 1994. He served as the President of Alkermes from July 1994 until his retirement in December 2001 and Chief Operating Officer from July 1994 to February 2001. From August 1991 to December 1993, Mr. Breyer was President and General Manager of Eli Lilly Italy, a subsidiary of Eli Lilly and Company. From September 1987 to August 1991, he was Senior Vice President, Marketing and Sales of IVAC Corporation, a subsidiary of Eli Lilly and Company. Mr. Breyer also serves on the Board of Directors of Lentigen.
David A. Broecker
David Broecker serves as President and Chief Executive Officer for Alkermes. From 2001-2007, David held the position of President and Chief Operating Officer for Alkermes, overseeing all aspects of product research and development, regulatory, quality and manufacturing, business development, and commercialization of products. Prior to joining Alkermes, David held various positions during a 14 year tenure at Eli Lilly and Company where he worked throughout Lilly's worldwide operations including manufacturing, process development, sales, marketing, and business development in both the pharmaceutical division and former medical device division (Guidant Corporation). He is a graduate of Wabash College with a B.A. in chemistry and mathematics. He also holds graduate degrees from the Massachusetts Institute of Technology in chemical engineering and the University of Chicago in business administration. David currently serves on the Advisory Board for the Center for Integrated Behavioral Health Policy at George Washington University.
Gerri Henwood
Ms. Henwood has been a director of Alkermes since April 2003. She is a consultant with Malvern Consulting Group. She was the co-founder and Chief Executive Officer of Auxilium Pharmaceuticals, Inc. Prior to founding Auxilium, Ms. Henwood founded, in 1985, a contract research organization (CRO), IBAH, Inc. Prior to founding IBAH, Ms. Henwood was employed by SmithKline Beecham in various capacities including senior medical and regulatory positions. Ms. Henwood is a member of the Board of Directors of MAP Pharmaceuticals, Inc. and is the CEO and Director of Recro Pharma Inc. She is also a trustee of LaSalle Academy.
Paul J. Mitchell
Mr. Mitchell has been a director of Alkermes since April 2003. He has served as the Chief Financial Officer and Treasurer of Kenet, Inc. since April 2002. Prior to joining Kenet, Mr. Mitchell was the Chief Financial Officer and Treasurer of Kopin Corporation from April 1985 through September 1998. From September 1998 through June 2001, Mr. Mitchell served in a consulting role at Kopin as Director of Strategic Planning. Prior to joining Kopin, Mr. Mitchell worked for the international accounting firm of Touche Ross & Co. from 1975 to 1984. Mr. Mitchell is also President of Mitchell Financial Group and a member of the Board of Directors of several private companies. Mr. Mitchell, a graduate of College of the Holy Cross (B.A. Economics) and Northeastern University (M.S. Accounting) is a Certified Public Accountant.
Alexander Rich
Dr. Rich is a founder of Alkermes and has been a director of Alkermes since 1987. Dr. Rich has been a professor at the Massachusetts Institute of Technology since 1958, and is the William Thompson Sedgwick Professor of Biophysics and Biochemistry. Dr. Rich earned both an A.B. (magna cum laude) and an M.D. (cum laude) from Harvard University. Dr. Rich is a member of the National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. Dr. Rich is Co-Chairman of the Board of Directors of Repligen Corporation, Inc., a member of the Scientific Advisory Board of Rosetta Genomics and a member of the Board of Directors for Profectus Biosciences, Inc.
Mark B. Skaletsky
Mr. Skaletsky has been a director of Alkermes since June 2004. He is currently Chairman, CEO and President of Trine Pharmaceuticals, Inc. Previously, Mr. Skaletsky was President and CEO of GelTex Pharmaceuticals, Inc. which was acquired by Genzyme in December 2000. Mr. Skaletsky held the position of Chairman and CEO of Enzytech, Inc., from 1988 to 1993, and he was President and Chief Operating Officer of Biogen, Inc., from 1981 to 1988. Mr. Skaletsky was among the founders of the Industrial Biotechnology Association, a predecessor to the Biotechnology Industry Organization (BIO), and is a former chairman of BIO. He serves on the Board of Directors of ImmunoGen, Inc, AMAG Pharmaceuticals, and Targacept, Inc. In addition, Mr. Skaletsky is a member of the Board of Trustees of Bentley College.